Trial · NCT00059202
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment Failure | 5 years | Treatment failure was defined as death, transplantation, meeting minimal listing criteria, development of varices, cholangiocarcinoma, or progression to cirrhosis |
| Secondary | Number of Deaths | 5 years | Death at any time up to 5 years |
| Secondary | Number of Participants Who Have a Liver Transplantation | 5 years | Liver transplantation at any time up to 5 years |
| Secondary | Number of Participants Meeting Minimal Listing Criteria for Liver Transplantation | 5 years | Meeting minimal listing criteria for liver transplantation at any time up to 5 years. Minimal listing criteria are defined as a MELD score of 14 or higher. The Model For End-Stage Liver Disease (MELD) is a numeric score with a range of 6 to 40, where a higher score means worse liver disease. |
| Secondary | Number of Participants Who Developed Cholangiocarcinoma | 5 years | Development of cholangiocarcinoma at any time up to 5 years |
| Secondary | Number of Participants Who Developed Varices | 5 years | Development of esophogeal and/or gastric varices |
| Secondary | Number of Participants Who Developed Cirrhosis | 5 years | Development of cirrhosis based on liver biopsy |
| Secondary | Alkaline Phosphatase at 12 Months | 12 months | Alkaline phosphatase divided by the upper limit of normal |
| Secondary | Alkaline Phosphatase at 24 Months | 24 months | Alkaline phosphatase divided by the upper limit of normal |
| Secondary | Alkaline Phosphatase at 36 Months | 36 months | Alkaline phosphatase divided by the upper limit of normal |
| Secondary | Aspartate Aminotransferase at 12 Months | 12 months | Aspartate aminotransferase at divided by the upper limit of normal |
| Secondary | Aspartate Aminotransferase at 24 Months | 24 months | Aspartate aminotransferase at divided by the upper limit of normal |
| Secondary | Aspartate Aminotransferase at 36 Months | 36 months | Aspartate aminotransferase at divided by the upper limit of normal |
| Secondary | Bilirubin at 12 Months | 12 months | Bilirubin divided by the upper limit of normal |
| Secondary | Bilirubin at 24 Months | 24 months | Bilirubin divided by the upper limit of normal |
| Secondary | Bilirubin at 36 Months | 36 months | Bilirubin divided by the upper limit of normal |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00059202/registered